ALNY — Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Net Product Revenues: Exceeded $1 billion for the first time, reaching $1.036 billion, up 121% year-over-year and 4% sequentially from Q4 2025.
• TTR Franchise Revenue: Generated $910 million, a 153% increase year-over-year and a 6% increase from Q4 2025.
• Rare Disease Revenue: Achieved $126 million, up 15% year-over-year.
• Gross Margin: 80%, down 5% from the previous year due to increased royalties on AMVUTTRA.
• Non-GAAP Operating Income: $339 million, over four times higher than the previous year.
• Cash Position: Ended the quarter with $3 billion in cash, cash equivalents, and marketable securities.

2. Strategic Updates and Business Highlights

• Leadership in TTR Amyloidosis: Continued strong performance in the TTR franchise with AMVUTTRA and ONPATTRO driving growth.
• New Collaborations: Entered partnerships aimed at enhancing TTR disease awareness and patient care pathways.
• Pipeline Progress: Over 25 clinical programs in development, including the initiation of a Phase I trial for ALN-2232 targeting obesity.
• Alnylam 2030 Vision: Focus on establishing global leadership in TTR, sustainable innovation, and disciplined growth.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Reiterated guidance of $4.4 billion to $4.7 billion for TTR product sales, expecting significant quarter-over-quarter growth.
• Pipeline Milestones: Anticipated updates and clinical readouts throughout 2026, including multiple Phase II trials and the expansion of the TRITON study.

4. Bad News, Challenges, or Points of Concern

• Collaboration Revenue Decline: Decreased by 17% year-over-year, primarily due to a $30 million milestone payment received in Q1 2025.
• Pricing Dynamics: Adjustments in Germany impacted revenues, although expected to stabilize as the CM indication launches.
• Insurance Reauthorization Headwinds: Faced challenges in the U.S. market, although demand growth was noted.
• Competitive Pressures: Concerns regarding upcoming competitor data and potential impacts on market dynamics, particularly with the introduction of new silencer therapies.

5. Notable Q&A Insights

• First-Line vs. Second-Line Use: Discussion highlighted the natural evolution of prescribing patterns, with a shift towards increased first-line use as physician experience grows.
• Impact of Selling Weeks: Clarified that fewer selling weeks in Q1 contributed to revenue dynamics, but overall demand remained strong.
• Competitive Landscape: Insights shared on how Alnylam's positioning and existing data support confidence in maintaining market share despite potential competitive pressures.
• Pricing Strategy: Management expressed confidence in maintaining pricing power and access, emphasizing the unique value proposition of AMVUTTRA.

Overall, Alnylam demonstrated strong financial performance in Q1 2026, with significant revenue growth driven by its TTR franchise. The company is well-positioned for future growth, although it faces challenges related to competition and pricing dynamics in international markets.